Phase I/II evaluation of RV1001, a novel PI3Kδ inhibitor, in spontaneous canine lymphoma

BACKGROUND: RV1001 is a novel, potent, and selective PI3Kδ inhibitor. The purpose of this study was to evaluate the safety and efficacy of RV1001 in canine Non-Hodgkin lymphoma (NHL). METHODS AND RESULTS: Inhibition of endogenous pAKT by RV1001 in primary canine NHL cells was determined by Western b...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardner, Heather L., Rippy, Sarah B., Bear, Misty D., Cronin, Kim L., Heeb, Heather, Burr, Holly, Cannon, Claire M., Penmetsa, Kumar V., Viswanadha, Srikant, Vakkalanka, Swaroop, London, Cheryl A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915681/
https://www.ncbi.nlm.nih.gov/pubmed/29689086
http://dx.doi.org/10.1371/journal.pone.0195357

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915681/
https://www.ncbi.nlm.nih.gov/pubmed/29689086
http://dx.doi.org/10.1371/journal.pone.0195357

Ejemplares similares